Article révisé par les pairs
Titre:
  • Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Auteur:Clotet, Bonaventura; Bellos, Nicholas; Molina, Jean-Michel; Cooper, David; Goffard, Jean-Christophe; Lazzarin, Adriano; Wöhrmann, Andrej; Katlama, Christine; Wilkin, Timothy; Haubrich, Richard; Cohen, Calvin; Farthing, Charles; Jayaweera, Dushyantha; Markowitz, Martin; Ruane, Peter; Spinosa-Guzman, Sabrina; Lefebvre, Eric; POWER 1 and 2 study groups,
Informations sur la publication:Lancet, 369, 9568, page (1169-1178)
Statut de publication:Publié, 2007-04
Sujet CREF:Médecine interne
MeSH keywords:Adult
Drug Administration Schedule
Drug Therapy, Combination
Female
HIV Infections -- drug therapy
HIV Protease Inhibitors -- administration & dosage -- adverse effects -- therapeutic use
HIV-1
Humans
Male
Middle Aged
RNA, Viral -- blood -- drug effects
Ritonavir -- administration & dosage -- adverse effects -- therapeutic use
Sulfonamides -- administration & dosage -- adverse effects -- therapeutic use
Viral Load
Note générale:Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0140-6736
info:doi/10.1016/S0140-6736(07)60497-8
info:pii/S0140-6736(07)60497-8
info:scp/34047207229
info:pmid/17416261

Documents en relation